Stephen Chia

23.6k total citations · 6 hit papers
234 papers, 11.5k citations indexed

About

Stephen Chia is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stephen Chia has authored 234 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Oncology, 123 papers in Cancer Research and 109 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stephen Chia's work include Breast Cancer Treatment Studies (95 papers), Advanced Breast Cancer Therapies (94 papers) and HER2/EGFR in Cancer Research (83 papers). Stephen Chia is often cited by papers focused on Breast Cancer Treatment Studies (95 papers), Advanced Breast Cancer Therapies (94 papers) and HER2/EGFR in Cancer Research (83 papers). Stephen Chia collaborates with scholars based in Canada, United States and Spain. Stephen Chia's co-authors include Torsten O. Nielsen, Maggie C.U. Cheang, Samuel Leung, Charles M. Perou, Karen A. Gelmon, David Voduc, Chris Bajdik, Caroline Speers, Dongxia Gao and Ivo A. Olivotto and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Stephen Chia

225 papers receiving 11.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. profile →
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

2008 945 citations Maggie C.U. Cheang, Samuel Leung et al. Clinical Cancer Research profile →
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

2013 774 citations Stephen Chia et al. Annals of Oncology profile →
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma

2001 364 citations Stephen Chia et al. Journal of Clinical Oncology profile →
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

2021 223 citations Hope S. Rugo, Patrick Neven et al. profile →
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021 161 citations Dennis J. Slamon, Patrick Neven et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Stephen Chia	7.4k	5.9k	3.2k	3.0k	1.4k	234	11.5k
Tomofumi Osako	6.0k 0.8×	5.7k 1.0×	5.2k 1.7×	2.2k 0.7×	1.3k 0.9×	42	12.1k
Yasuo Toyozumi	5.8k 0.8×	5.5k 0.9×	5.2k 1.6×	2.2k 0.7×	1.3k 0.9×	37	11.8k
Reiki Nishimura	6.8k 0.9×	6.2k 1.0×	5.4k 1.7×	2.6k 0.9×	1.5k 1.1×	131	13.3k
Mamiko Fujisue	5.5k 0.7×	5.4k 0.9×	5.1k 1.6×	2.1k 0.7×	1.2k 0.9×	18	11.4k
Rumiko Tashima	5.6k 0.8×	5.4k 0.9×	5.1k 1.6×	2.1k 0.7×	1.2k 0.9×	21	11.5k
Aňa Lluch	10.3k 1.4×	6.1k 1.0×	4.1k 1.3×	2.5k 0.8×	1.2k 0.8×	306	14.7k
Semiglazov Vf	8.5k 1.1×	5.6k 0.9×	2.1k 0.7×	2.1k 0.7×	1.5k 1.0×	239	11.9k
Lyndsay N. Harris	9.3k 1.3×	5.5k 0.9×	5.1k 1.6×	2.9k 0.9×	1.2k 0.9×	192	15.0k
Aleix Prat	8.9k 1.2×	6.1k 1.0×	5.8k 1.8×	3.5k 1.2×	1.1k 0.8×	395	14.7k
Elżbieta Senkus	6.2k 0.8×	4.0k 0.7×	2.3k 0.7×	2.5k 0.8×	1.2k 0.8×	113	10.1k

Countries citing papers authored by Stephen Chia

Since Specialization

Citations

This map shows the geographic impact of Stephen Chia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Chia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Chia more than expected).

Fields of papers citing papers by Stephen Chia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Chia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Chia. The network helps show where Stephen Chia may publish in the future.

Co-authorship network of co-authors of Stephen Chia

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Chia. A scholar is included among the top collaborators of Stephen Chia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Chia. Stephen Chia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fasching, Peter A., Dennis J. Slamon, Zbigniew Nowecki, et al.. (2025). Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. Clinical Cancer Research. 31(9). 1625–1635. 2 indexed citations

Mamounas, Eleftherios P., Hanna Bandos, Priya Rastogi, et al.. (2024). Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Clinical Cancer Research. 30(9). 1984–1991. 7 indexed citations

Kalinsky, Kevin, William E. Barlow, Harsh B. Pathak, et al.. (2024). Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).. Journal of Clinical Oncology. 42(16_suppl). 505–505. 5 indexed citations

Valenza, Carmine, Dario Trapani, Sibylle Loibl, et al.. (2024). Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response. Journal of Clinical Oncology. 42(20). 2372–2376. 2 indexed citations

Luzhna, Lidiya, et al.. (2024). Abstract PO3-15-04: Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive, HER2-negative Breast Cancers. Cancer Research. 84(9_Supplement). PO3–15.

Titmuss, Emma, Robert J. Vanner, David F. Schaeffer, et al.. (2024). Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. Cancer Research Communications. 5(1). 66–73. 2 indexed citations

Cao, Jeffrey, Jean-François Boileau, Karen A. Gelmon, et al.. (2024). Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer. Current Oncology. 31(11). 7226–7243. 2 indexed citations

O’Shaughnessy, Joyce, Stephen Chia, Claudine Isaacs, et al.. (2023). 196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2. ESMO Open. 8(1). 101385–101385.

Henning, Jan‐Willem, Christine Brezden‐Masley, Karen A. Gelmon, et al.. (2023). Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective. Current Oncology. 30(9). 8019–8038. 17 indexed citations

10.

Neven, Patrick, PA Fasching, Stephen Chia, et al.. (2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research. 25(1). 103–103. 33 indexed citations

11.

Sit, Daegan, Nafisha Lalani, Elisa Chan, et al.. (2021). Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 112(4). 861–869. 2 indexed citations

12.

LeVasseur, Nathalie, David Fenton, Simon W. Baxter, et al.. (2021). Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study. Clinical Breast Cancer. 22(1). e74–e79. 9 indexed citations

13.

Turner, Nicholas C., Claire Swift, Lucy Kilburn, et al.. (2020). ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. Clinical Cancer Research. 26(19). 5172–5177. 100 indexed citations

14.

Chia, Stephen, Vivien Bramwell, Dongsheng Tu, et al.. (2012). A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Clinical Cancer Research. 18(16). 4465–4472. 220 indexed citations

15.

Cheang, Maggie C.U., K. David Voduc, Dongsheng Tu, et al.. (2012). Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. Clinical Cancer Research. 18(8). 2402–2412. 105 indexed citations

16.

Chia, Stephen. (2011). Year in review for local/triple negative/cytotoxic therapy (ASCO 2011) (The 49th annual meeting of Japanese Society of Clinical Oncology educational book) -- (JSCO University: Breast cancer). 46(3). 1172–1175. 1 indexed citations

17.

Seal, Melanie & Stephen Chia. (2010). What Is the Difference Between Triple-Negative and Basal Breast Cancers?. The Cancer Journal. 16(1). 12–16. 35 indexed citations

18.

Lavasani, Sayeh, John R. Mackey, Kathleen I. Pritchard, et al.. (2010). Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology. 17(4). 20–33. 23 indexed citations

19.

Batist, Gerald, Karen A. Gelmon, Kim N., et al.. (2009). Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(2). 692–700. 166 indexed citations

20.

Rayson, Daniel, D. J. Richel, Stephen Chia, et al.. (2008). Anthracycline–trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Annals of Oncology. 19(9). 1530–1539. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact